CUE — Cue Biopharma
NASDAQ · Healthcare · Biotechnology
$28.32
-$0.12 (-0.42%)
Cue Biopharma (CUE) is a biotechnology company listed on NASDAQ. It is led by Daniel R. Passeri J.D., M.Sc., based in 40 Guest Street, Boston, MA, United States, 02135, with about 41 employees. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Latest reported CUE revenue for 2025-09-30 was $2.1M. Net income was -$28.2M. Revenue was down 27.3% from 2025-06-30 to 2025-09-30. CUE currently screens at market cap $59.5M.
Use this CUE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CUE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CUE SEC filings page. Lician reads the product cache first so this HTML stays unique to Cue Biopharma even when a live quote feed is slow.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
CUE Key Statistics
Market Cap
$59.48M
Volume
111,838
Previous Close
$23.18
Day Range
$23.41 – $28.29
EPS
-$0.72
Revenue
$9.29M
Net Income
-$40.67M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+69.2%
Profit Margin
-438.0%
Employees
41
CUE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.29M | $5.49M | $1.25M | $14.94M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$40.67M | -$50.73M | -$53.01M | -$44.16M |
| EPS (Diluted) | -$0.72 | -$1.11 | -$1.49 | -$1.41 |
Total Assets
$32.19M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.46M
Operating Cash Flow
-$36.33M
Free Cash Flow
$0.00
Cue Biopharma Company Information
- CEO, Interim Principal Financial and Accounting Officer & Director
- Daniel R. Passeri J.D., M.Sc.
- Headquarters
- 40 Guest Street, Boston, MA, United States, 02135
- Website
- www.cuebiopharma.com
- Phone
- 617 949 2680
- IPO / Founded
- 2018-01-02
- Sector
- Healthcare
- Industry
- Biotechnology